Xian-Ke Lin's research while affiliated with First Affiliated Hospital of China Medical University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
Background: The leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5) is considered a cancer stem cell marker, and is often overexpressed in tumors. The interaction between Lgr5 and the immune-related tumor microenvironment is not completely understood. The aim of this study was to examine the role of Lgr5 in the microenvironment of ga...
A 67-year-old female presented with a primary hepatic gastrointestinal stromal tumor that was detected by computed tomography and diagnosed based on histopathological and genetic analyses. The tumor was microscopically composed of spindle cells and epithelioid cells, and immunohistochemistry results showed positive staining for CD117 and CD34 expre...
Regulatory T cells (Tregs) and plasmacytoid dendritic cells (pDCs) play important roles in the immune escape of cancer. In this study, we investigated pDCs and pDCs induced ICOS(+) Tregs population in peripheral blood from gastric cancer (GC) patients and healthy donors by flow cytometry. The distribution of these cells in carcinoma tissue, peritum...
Mitofusin-2 (Mfn2) is a mitochondrial outer membrane protein involved in mitochondrial fusion. Its mutation can cause Charcot-Marie-Tooth disease. Recent studies of Mfn2 in cancer research have not included gastric cancer. We confirmed that Mfn2 expression was lower in tumor tissue than in normal gastric mucosal tissue and that it was negatively co...
Citations
... LGR5 is a Wnt target gene and it has been identified as a CSC marker in intestinal cells (11). Its ability to maintain CSCs and promote cancer progression has been observed in various types of cancer, including breast, colorectal, hepatocellular, gastric, and ovarian cancers (12)(13)(14)(15). Recent studies showed that LGR5 expression levels could predict prognosis, recurrence, and survival rates in some cancer types (16,17). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/445584629866497-1483247062378_Q64/Xiaosun-Liu.jpg)
... Both the cell membrane and cytoplasm of our patient's tumor samples were highly CD117-positive. The final primary hepatic EGIST diagnosis was based on the fact that (1) no abnormal mass was identified in any other organs except for the liver and (2) there was no evidence of other primary hepatic tumor or GIST metastases (12). Additionally, pre-, intra-, and post-operative assessment and imaging examinations, including EGD, colonoscopy, ultrasonography, and CT, revealed that the tumor was confined to the liver. ...
... Conversely, increased ICOS + Treg in TILs has been reportedly associated with poor prognosis in gastric cancer. 41 The mechanisms of tumor growth and antitumor immunity may differ depending on the ICOS/ICOSL expression pattern in cancer tissues. Further studies on the function of ICOS in antitumor immunity mechanisms are required. ...
![[object Object]](https://c5.rgstatic.net/m/4671872220764/images/template/default/profile/profile_default_m.jpg)
... With the advancement of precision tumour therapy, new biological markers are urgently needed for definitive diagnosis and precise treatment [29,30].In this study, analysis of the TCGA database clarified that MFN2 was significantly low expressed in renal clear cell carcinoma relative to normal kidney tissue.It has been shown that MFN2 shows low expression in breast cancer, and MFN2 can inhibit mTORC2 expression and inhibit tumor growthby binding to mTORC2 domain HR1 [31] .A study on gastric cancer showed that the expression of MFN2 was lower than that in normal gastric mucosa tissue, and after overexpressed MFN2, it downregulated the expression of MMP-2 and MMP-9 attenuated the invasion and migration ability of cancer cells by inhibiting PI3K/Akt signaling and inhibited tumor progression [32].MFN2 regulates mitochondrial fusion / division in cells in thyroid cancer and affects cellular metabolism, which regulates EMT in tumors through induction of the AKT signaling pathway [33].In ovarian cancer, increased expression of MFN2 triggers AMPK, promotes autophagy, reduces ROS, and suppresses ovarian cancer progression through downregulation of p-mTOR and p-ERK axis [34] .MFN2 is highly expressed in cervical cancer, and the knockout of MFN2 can significantly inhibit the proliferation and EMT of cervical cancer cells, becoming a new target for the treatment of tumors [35].MFN2 expression was significantly downregulated in bladder cancer cells, and it can inhibit the Wnt/β-catenin signaling pathway to inhibit tumor progression through [36].MFN2 induces autophagy and promotes apoptotic in pancreatic cancer cells by inhibiting the PI3K/Akt/mTOR signaling pathway in pancreatic cancer [37].However, how MFN2 is expressed and how it functions in renal clear cell carcinoma is unclear and requires further study.In our study, MFN2 showed low expression and correlated with worse pathological stage, T-stage, histological grade, and M-stage.In addition, we found that low expression of MFN2 was associated with poorer OS, DSS and PFI, and univariate and multifactorial COX regression analyses showed that MFN2 expression was an important independent prognostic factor for renal clear cell carcinoma. Taken together, MFN2 could be a new molecular candidate to treat renal clear cell carcinoma. ...
